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Abstract
Background: Pancreatic neoplasms are usually characterized by ductal, acinar, or endocrine differentiation. Mixed exocrine
and endocrine pancreatic tumours are extremely rare. Here, we report a case of pancreatic mixed acinar-endocrine
carcinoma (MAEC) with multiple synchronous liver metastases that were treated with surgery and transcatheter arterial
chemoembolization (TACE) that later recurred in the stomach.
Case presentation: A 45-year-old female with severe anaemia was referred to our hospital. Computed tomography
(CT) demonstrated a hypervascular tumour, 17 cm in diameter, that was in the tail of the pancreas. In addition, there
were multiple hypervascular tumours in the liver. She underwent a distal pancreatectomy with splenectomy after the
liver metastases were treated with TACE. Pathology confirmed that the pancreatic tumour was MAEC. After 4.5 years, a
follow-up CT showed a hypervascular tumour at the upper part of the stomach. Gastric endoscopy showed a big
tumefactive lesion with surface irregularities, gastric erosion, and multiple dilated vessels in the fornix and greater
curvature of the stomach. She underwent a proximal gastrectomy and survived 7 years and 2 months after the start of
the treatment.
Conclusions: This is the first report of a metastatic stomach tumour from pancreatic MAEC, which was successfully
treated with a multidisciplinary approach. Additionally, we review the literature and discuss the treatment of MAEC.
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Background
Mixed acinar-endocrine carcinoma (MAEC) is a rare
neoplasm that is mainly observed in the pancreas. Ac-
cording to the WHO classification, MAEC is defined as
a variant of acinar cell carcinoma and should have an
endocrine component in more than 30% of tumour cells
[1, 2]. However, the biological behaviours, treatment
strategies, and overall prognosis for patients with MAEC
are still unclear. Here, we report the case of a patient
with pancreatic MAEC with multiple liver metastases
who underwent distal pancreatectomy and catheter-
directed treatment to the liver. She subsequently
developed a metastatic tumour to the stomach 4.5 years
later. She was successfully treated with a proximal
gastrectomy for the metastatic stomach tumour. This is
the first report of a metastatic stomach tumour from
pancreatic MAEC that was successfully treated with a
multidisciplinary approach. To date, 12 cases of pancre-
atic MAEC that met criteria by the WHO classification
have been reported in the English literature, which we
identified by a PubMed search [3–10]. We review the
literature and discuss the treatment for MAEC.
Case presentation
The patient was a 45-year-old female who presented
with severe anaemia (Hb 4.7 g/dl) on a laboratory test
performed by a local doctor. Gastroscopy revealed
gastric varices with blood oozing and an extrinsic
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compression in the gastric wall. Her anaemia was
improved by transfusion and oral iron preparation. On
physical examination, she had a soft, non-tender abdo-
men without any palpable masses. The laboratory data
showed the following: Hb 11.8 g/dl (reference range,
12–15 g/dl), aspartate aminotransferase (AST) 12 U/l
(13–33 U/l), alanine transaminase (ALT) 7 U/l (6–27 U/
l), total bilirubin 0.2 mg/dl (0.2–1.2 mg/dl), and total
amylase 49 IU/l (33–120 IU/l). Tumour marker levels
were as followed: carcinoembryonic antigen (CEA)
2.5 ng/ml (<5 ng/ml), cancer antigen 19-9 (CA19-9)
0 U/ml (0–36 U/ml), DUPAN-II 215 U/ml (<150 U/ml),
and elastase 281 ng/dl (28–254 ng/dl). She had no spe-
cific medical or family history of this disease. Computed
tomography (CT) demonstrated a hypervascular tumour
that was 17 cm in the tail of the pancreas, infiltrating
the spleen and the splenic vein (Fig. 1a). In addition,
there were multiple hypervascular tumours in the liver
(Fig. 1b). CT-guided core needle biopsy of a liver tumour
was performed, and pathological examination revealed
well-differentiated endocrine carcinoma originating from
the pancreas. She was diagnosed with pancreatic endo-
crine carcinoma with multiple liver metastases. First,
transcatheter arterial chemoembolization (TACE) with
epirubicin 50 mg + Lipiodol 7 ml + GS cube was per-
formed to treat the liver metastases. After confirmation
that the liver metastases were under control, she under-
went distal pancreatectomy and regional lymph node
dissection with splenectomy. Pathological examination
showed that the pancreatic tumour was MAEC. She was
followed without any treatment including TACE after
surgery. Four years and 5 months later, routine haema-
tology labs showed progressive anaemia, and CT showed
a hypervascular tumour located in the upper part of the
stomach (Fig. 1c). The liver metastases were stable.
Gastric endoscopy showed a large tumefactive lesion
with surface irregularities, gastric erosion and multiple
dilated vessels in the fornix and greater curvature of the
stomach (Fig. 1d). Biopsies performed during endoscopy
confirmed metastatic gastric tumour from MAEC.
Therefore, she underwent a proximal gastrectomy with
cholecystectomy for gallstone disease with double-tract
reconstruction. The patient survived for 2 years and
7 months after gastrectomy, although TACE was
performed for the recurred liver metastasis twice.
Macroscopic and microscopic examination
The resected pancreas tumour measured 11 cm and was
in the tail of the pancreas, infiltrating the spleen and the
splenic vein (Fig. 2a, b). Tumour thrombus was found
from the main tumour to the splenic vein. However, no
lymphatic invasion and no regional lymph node metastasis
were identified. The resected gastric tumour measured
10 cm in the fornix and greater curvature (Fig. 2c, d).
Histology confirmed a cellular neoplasm originating
from the pancreatic parenchyma. Two distinct popula-
tions of neoplastic cells were present. Many tumour cells
grew in solid nests and included acinar and glandular
structures (Fig. 3a). Immunohistochemistry (IHC)
studies demonstrated strong co-expression of acinar and
Fig. 1 Abdominal contrast-enhanced CT findings and upper endoscopy findings. CT showing a hypervascular tumour in the tail of the pancreas,
infiltrating the spleen and the splenic vein (a). Multiple hypervascular tumours in the liver (b). Hypervascular tumour in the upper part of the
stomach (c). Upper endoscopy showing a big tumefactive lesion in the fornix and greater curvature (d)
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endocrine markers in all the tumour cells (Fig. 3b, c).
Most of the tumour was positive for trypsin, an acinar
cell marker (more than 90% of the tumour), and many
cells were positive for chromogranin A, an endocrine
marker (40–50% of the tumour). Histology confirmed a
cellular neoplasm originating from the gastric tumour
that showed acinar arrangement or glandular formation
with eosinophilic secretory material (Fig. 3d). Immuno-
histochemical staining of metastatic gastric tumour was
positive for both trypsin and chromogranin A in more
than 40% of the tumour (Fig. 3e, f ). Therefore, the
patient was diagnosed with MAEC metastatic to the
stomach.
Discussion
The pancreas is well known to be composed of two
entirely different components, the exocrine and the endo-
crine pancreas. The exocrine pancreas is composed mainly
of duct cells with some contribution from acinar cells,
whereas the endocrine pancreas consists of islet cells. One
Fig. 2 Photograph of Surgical specimen. Pancreas tumour measuring 11 cm, which was white in colour and well demarcated, had expansive
lobular growth, and was located in the tail of the pancreas, infiltrating the spleen and the splenic vein (a, b). Gastric tumour measured 9 cm.
Tumour was white in colour with a distinct border and had expansive growth under the submucosa (c, d)
Fig. 3 Histopathological features of the mixed acinar-endocrine carcinoma. Haematoxylin and eosin image of the pancreas tumour, 100× (a).
Immunostaining of the pancreas tumour for trypsin 100× (b) and chromogranin A 100× (c). Haematoxylin and eosin image of the gastric tumour,
50× (d). Immunostaining of the gastric tumour for trypsin 50× (e) and chromogranin A 50× (f)
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of the most important features of pancreatic neoplasms is
the type of differentiation of the cancer cells, which deter-
mines the classification of the tumour. Most pancreatic
epithelial neoplasms recapitulate to some degree one or
more of the normal epithelial cell types of the pancreas:
ductal (75–90%), acinar (1–2%), and endocrine (3–7%)
[11]. Some pancreatic neoplasms have significant compo-
nents from more than one line of differentiation and are
classified as mixed acinar-endocrine carcinomas (MAEC),
mixed acinar-ductal carcinomas, mixed ductal-endocrine
carcinomas, or mixed acinar-endocrine-ductal carcinomas
[2]. By arbitrary definition, each component must
comprise at least 25% of the neoplasm [3, 12]. Only 21
cases that fit this strict definition have been reported in
the English literature.
Table 1 summarizes the 21 cases of pancreatic MAEC
that have both acinar and endocrine components in more
than 25% of tumour cells by immunohistochemistry
reported in the English literature, excluding the cases
diagnosed only by biopsy [1, 3–10, 13–15]. In these re-
ports, 16 of the 21 patients with confirmed MAEC of the
pancreas were male (76%). The median age was 65 years
(range 45–89 years), and our case involved the youngest
patient. MAECs were most commonly located in the head
of the pancreas. The median tumour size of MAECs was
7.3 cm. Nineteen patients underwent surgical resection, 1
patient underwent bypass surgery (gastrojejunostomy),
and the remaining 1 patient received chemotherapy only.
Out of the 19 patients who underwent surgical resection,
2 received preoperative chemotherapy, 16 patients under-
went curative surgery, and 6 patients received adjuvant
chemotherapy. Pathological examination of the surgical or
autopsy specimens showed that 12 tumours had predo-
minately solid morphology, 6 had predominately acinar
morphology, and the other 3 had both morphologies in
equal parts. Immunohistochemistry revealed that 6
tumours had predominately endocrine components, 10
had predominately acinar components, and the other 5
contained equal amounts of both components or showed
a co-expression pattern. Eight reports including the
current case mentioned on the status of regional lymph
node metastases and 4 (50%) out of 8 patients had lymph
node metastases [1, 3, 5, 6, 10, 13, 14]. Ten (48%) out of
all 21 patients with confirmed MAEC of pancreas had dis-
tant metastases. One patient had metastases in multiple
organs; however, the details were not provided [5]. The
remaining 9 patients had liver metastases. Additional
metastasis was observed in kidney, lung, and stomach in
the current case.
Pancreatic MAEC is very rare with only 21 cases reported
in the English literature, as shown in Table 1. Therefore,
precise clinical features of MAEC are not well understood
and no standard treatment has been established. According
to previous reports, the prognosis of MAEC was poor simi-
lar to that of acinar cell carcinoma [3, 7]. The prognosis of
16 cases who underwent surgical resection for pancreatic
MAEC was analysed; 1-year overall survival rate was 80%
and 3-year survival rate was 60% by Kaplan-Meier method
[1, 3, 5–7, 9, 10, 14]. We performed a pancreatectomy for
pancreas MAEC after arterial catheter embolization for
multiple liver metastases. Furthermore, a proximal gastrec-
tomy was also performed for a stomach recurrence, which
occurred 4.5 years after the first surgery. The patient
Table 1 Summarizing statistics of cases of mixed acinar-endocrine
pancreatic carcinoma (21 cases including the present case)





















Surgical resection 11 (52%)
Surgical resection














Multiple organs 1 (5%)
Hara et al. Surgical Case Reports  (2017) 3:51 Page 4 of 5
survived more than 7 years after she was first diagnosed
with pancreatic MAEC and survived for longest term after
surgical resection in comparison with previous reports. Be-
cause there are no promising anti-tumour therapies, such
as chemotherapy or chemoradiation, surgical resection is
the first-line therapy for resectable cases of MAEC. Local
therapy, such as catheter-directed embolization, is also
promising for multiple liver metastases, which is the most
common site of metastasis from pancreatic MAEC.
Conclusions
In conclusion, we presented here a very rare case of
metastatic gastric tumour from pancreatic MAEC with
multiple liver metastasis. This is the first report of
metastasis to the stomach from pancreatic MAEC. The
stomach should be considered a target site of metastasis
during the treatment of pancreatic MAEC. A multidis-
ciplinary approach with surgery and TACE for liver
metastases might be a promising therapeutic approach
for patients with advanced cases of MAEC.
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